No abstract

Breast cancer is the leading cause of death among women, with approximately 1 million diagnoses annually. Triterpenoids, which have cancer preventive or anti-tumour efficacy towards various tumour cells, may play a role in breast cancer prevention. In our previous study, an acetic ether (EtOAc) fraction from the sporocarp of the edible mushroom Pleurotus eryngii (P. eryngii) exhibited significant tumour cell growth inhibition both in vitro and in vivo. In this study, three pentacyclic triterpenoid compounds (1-3) were isolated from EtOAc extracts using chromatographic separation and were identified using nuclear magnetic resonance (NMR) and mass spectrometry (MS). The compounds were 2, 3, 6, 23-tetrahydroxy-urs-12-en-28 oic acid (1), 2,3,23-trihydroxy-urs-12-en-28 oic acid (2) and lupeol (3). All three purified triterpenes showed significant inhibitory activity against breast cancer MCF-7 cell lines in vitro, with the greatest activity exhibited by compound 1, followed by compound 2 and 3. The IC(50) values were 15.71, 48 and 66.89 μM, respectively. Our study may help elucidate the health benefits of P. eryngii mushroom consumption.

No abstract

It was previously found that CPe-III-S, synthesized according to the chickpea peptide CPe-III (RQSHFANAQP), exhibited an antiproliferative effect. The aim of this study was to investigate the antiproliferative mechanism of CPe-III-S. CPe-III-S was treated by pepsin and trypsin in a simulated gastrointestinal digestion environment as well as in an animal experiment. With HPLC-ESI-MS analysis, three peptide fragments of Ser-His, His-Phe, and Ala-Asn-Ala-Gln were identified. Ser-His was the only common product from both in vitro and in vivo environments. The specific bindings between three peptides and p53-R273H were performed by molecular docking, and the molecular dynamic simulation between Ser-His and p53-R273H revealed the stability of the binding complex. The binding free energy of the complex was -12.56 ± 1.03 kcal/mol with a reliable hydrogen bond between the ligand and Thr284 of p53. Ser-His may restore mutant p53-R273H activity or inhibit its binding with a downstream signal. This metabolite is a potential anticancer factor for suppressing cell proliferation.